Palliative Radiotherapy Protocol in Head and Neck Cancer
Launched by MAISONNEUVE-ROSEMONT HOSPITAL · Jun 1, 2015
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
Patients deemed too frail for radical treatment or incurable because of tumour extension, as determined by an experienced tumour board, were eligible for this study of palliative radiotherapy delivered by intensity modulation, 25 Gy in 5 daily fractions over one week. This study was conducted in two academic centers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to give an informed consent
- • Able to complete QOL questionnaires
- • Deemed incurable by an experienced tumour board or unwilling to receive a radical course of radiation therapy
- • Presence of measurable disease
- • Biopsy proven squamous or salivary cancer of the head and neck region
- • Expected survival of at least 2 months.
- Exclusion Criteria:
- • Pregnancy
- • No previous RT to the neck and no plan to receive concomitant chemotherapy
- • Special histology (Lymphoma, small cell cancer, metastasis from a site other than the head and neck region)
- • Unavailable for follow-up
About Maisonneuve Rosemont Hospital
Maisonneuve-Rosemont Hospital, a leading healthcare institution in Montreal, Canada, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the hospital leverages its state-of-the-art facilities and expertise in various specialties to conduct rigorous clinical studies. Committed to ethical standards and patient safety, Maisonneuve-Rosemont Hospital fosters an environment that encourages scientific inquiry and the translation of research findings into clinical practice, ultimately aiming to enhance treatment options and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Bernard Fortin, MD MSc
Principal Investigator
Maisonneuve Rosemont Hospital, University of Montreal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials